Incidence of cancer in patients with spondyloarthritis treated with anti-tnf drugs

Of the 3321 SpA patients (1731 males, 52.2%; mean age 47±13 years; median disease duration three years, interquartile range [IQR] 0-8), 50 developed at least one of 56 malignancies during the follow-up period of up to 12 years of treatment with TNFi. The overall incidence was 6.3/1000 patient-years of follow-up (95% confidence interval [CI] 4.7-8.2): 7.3/1000 patient-years (95% CI 4.1-11.8) in those treated with ADA; 6.1/1000 patient-years (95% CI 3.8-9.4) in those treated with ETN; and 5.8/1000 patient-years (95% CI 3.5-9.1) in those treated with INF while in the general population was 5.1/1000 patient-years. Univariate analysis showed that age at the time of starting TNFi (p=0.001), the presence of comorbidities (p=0.012), the number of comorbidities (p